A 24-year-old woman has excelled at her receptionist job at a prominent cosmetic dermatology office. She is an employee at will; that is, she has no employment contract. She has recently attended a conference at which Basal Cell Nevus Syndrome is discussed. At that time she discloses that, although she has no stigmata for the disease, she has a strong family history for this genetically transmitted disease. Shortly thereafter she is terminated from her job. She is not given a reason for the termination but suspects it is related to her genetic predisposition.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.